How Would You Treat These Patients? A Live Virtual Clinic in PAH

Pulmonary arterial hypertension (PAH) is a rare but serious and progressive condition with poor prognosis. The current approach to management of PAH is according to the severity of disease at the time of diagnosis. Over the past 10 years, advances in PAH treatment and patient care have improved the morbidity and mortality rates for patients with PAH. Various therapies that target a variety of different pathways involved in PAH pathogenesis now allow clinicians to provide multimodal treatment to further optimize patient outcomes. Additionally, data about new therapies and evolving PAH treatment paradigms continue to emerge with the potential to influence patient care. New therapies have provided major improvement to quality of life in patients with PAH. They have been integrated into iterations of clinical practice guidelines to guide appropriate clinical decisions for effective PAH management, however, there is a continual delay in diagnosis and a need to improve therapeutic selection and strategies to enhance overall patient care. In this interactive live symposium, experts in the field of PAH will engage in discussion and dissect a variety of patient cases that address best practices for recognizing, diagnosing, and treating PAH in clinical practice to improve patient outcomes. By participating in this activity, learners will gain insight to evidence-based approaches to appropriate risk assessment in PAH, guideline-directed strategies to set and treat to specific PAH treatment goals, best practices to tailor and/or adjust PAH therapy to meet treatment goals and achieve low-risk status, as well as approaches to effectively monitor PAH patients throughout the course of the disease.

Upon completion of this activity, learners will have greater competence related to:

  • Patient assessment strategies to determine risk status for patients with PAH
  • Selection of appropriate PAH therapy to achieve low-risk status
  • Use of effective strategies to address adherence and tolerance in patients with PAH

Presented By:

Vallerie McLaughlin, MD
Professor of Cardiovascular Medicine
Director, Pulmonary Hypertension Program
University of Michigan
Ann Arbor, Michigan

Murali Chakinala, MD
Professor of Medicine
Director, Washington University and Barnes-Jewish Hospital Pulmonary Hypertension Care Center
Washington University
St Louis, Missouri